BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27108529)

  • 1. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.
    Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G
    Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
    Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
    Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
    J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
    van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
    Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
    Barefield D; Kumar M; de Tombe PP; Sadayappan S
    Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
    Suay-Corredera C; Alegre-Cebollada J
    FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
    Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
    Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
    van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
    Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
    Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
    Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
    De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
    J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
    Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.
    Flavigny J; Souchet M; Sébillon P; Berrebi-Bertrand I; Hainque B; Mallet A; Bril A; Schwartz K; Carrier L
    J Mol Biol; 1999 Nov; 294(2):443-56. PubMed ID: 10610770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
    Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
    J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure.
    Doh CY; Li J; Mamidi R; Stelzer JE
    Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):661-677. PubMed ID: 30611859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
    Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
    Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.